Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Maraviroc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maraviroc SCHEMBL20451355 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL4576508 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL1053748 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL2177194 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL51991 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611449 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611504 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL30852775 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611605 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL14168620 | 0.94 | CCR5 (0.89) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205209-A1 | Methods of Treating a Subject for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Compositions for Use in The Same | INCELLDX, INC. | 2025-06-26 | — | — | US | claimed |
| US-20250205220-A1 | Methods of Treating a Subject for Post-Treatment Lyme Disease (PTLD) and Compositions for Use in the Same | INCELLDX, INC. | 2025-06-26 | — | — | US | claimed |
| US-20250099444-A1 | Methods of Treating a Subject for Long-Haul COVID-19, and Compositions for Use in the Same | INCELLDX, INC. | 2025-03-27 | — | — | US | claimed |
| EP-4499098-A1 | METHODS OF TREATING A SUBJECT FOR MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) AND COMPOSITIONS FOR USE IN THE SAME | IncellDx, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| EP-4469160-A1 | METHODS OF TREATING A SUBJECT FOR LONG-HAUL COVID-19, AND COMPOSITIONS FOR USE IN THE SAME | IncellDx, Inc. (US) | 2024-12-04 | — | — | EP | claimed |
| WO-2023192362-A1 | METHODS OF TREATING A SUBJECT FOR MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) AND COMPOSITIONS FOR USE IN THE SAME | INCELLDX, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023192361-A1 | METHODS OF TREATING A SUBJECT FOR FIBROMYALGIA AND COMPOSITIONS FOR USE IN THE SAME | INCELLDX, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023146812-A1 | METHODS OF TREATING A SUBJECT FOR LONG-HAUL COVID-19, AND COMPOSITIONS FOR USE IN THE SAME | INCELLDX, INC. (US) | 2023-08-03 | — | — | WO | claimed |
| US-9993547-B2 | T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines | IMMUNOMEDICS, INC. (US) | 2018-06-12 | — | — | US | claimed |
| EP-3303370-A1 | T20 CONSTRUCTS FOR ANTI-HIV (HUMAN IMMUNODEFICIENCY VIRUS) THERAPY AND/OR VACCINES | Immunomedics, Inc. (US) | 2018-04-11 | — | — | EP | claimed |
| US-7576097-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2009-08-18 | — | — | US | claimed |
| EP-1990341-A1 | Triazolyl tropane derivatives as CCR5 modulators | Pfizer Inc. (US) | 2008-11-12 | — | — | EP | claimed |
| US-20080132537-A1 | TROPANE DERIVATIVES USEFUL IN THERAPY | PFIZER INC | 2008-06-05 | — | — | US | claimed |
| US-7368460-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2008-05-06 | — | — | US | claimed |
| US-20040067977-A1 | Tropane derivatives useful in therapy | PFIZER, INC. | 2004-04-08 | — | — | US | claimed |
| EP-1284974-B1 | TRIAZOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LTD (GB) | 2004-03-03 | — | — | EP | claimed |
| US-6667314-B2 | For therapy of respiratory disorder including adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis or chronic sinusitis | PFIZER, INC. | 2003-12-23 | — | — | US | claimed |
| EP-1284974-A2 | TRIAZOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | Pfizer Limited (GB) | 2003-02-26 | — | — | EP | claimed |
| US-20020013337-A1 | Tropane derivatives useful in therapy | PHIVCO-1 LLC | 2002-01-31 | — | — | US | claimed |
| WO-2001090106-A2 | TRYASOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2001-11-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099444-A1 | Methods of Treating a Subject for Long-Haul COVID-19, and Compositions for Use in the Same | CCR5, CCL5, CCL11 | CCR5 1/4885KCNH2 4849/4885CYP3A4 545/4885 |
| US-20250205220-A1 | Methods of Treating a Subject for Post-Treatment Lyme Disease (PTLD) and Compositions for Use in the Same | CCR5, CCL5, CCL11 | CCR5 1/4885KCNH2 4880/4885CYP3A4 2753/4885 |
| US-20250205209-A1 | Methods of Treating a Subject for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Compositions for Use in The Same | CCR5, CCL5, CCL11 | CCR5 1/4885KCNH2 4746/4885CYP3A4 1573/4885 |
| US-20020013337-A1 | Tropane derivatives useful in therapy | ADRB3, ADRA1A, ADRB2 | CCR5 385/4885KCNH2 1032/4885CYP3A4 246/4885 |
| US-20040067977-A1 | Tropane derivatives useful in therapy | ADRB3, ADRA1A, ADRB2 | CCR5 385/4885KCNH2 1032/4885CYP3A4 246/4885 |
| US-20080132537-A1 | TROPANE DERIVATIVES USEFUL IN THERAPY | ADRB3, ADRB2, ADRA2C | CCR5 407/4885KCNH2 1335/4885CYP3A4 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.